{
    "clinical_study": {
        "@rank": "78959", 
        "acronym": "SR-GS", 
        "arm_group": {
            "arm_group_label": "S-1-CCRT", 
            "arm_group_type": "Experimental", 
            "description": "There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether combination of TS-1 and concurrent and\n      short-course radiotherapy is feasible in metastatic pancreatic cancer. The rationale of this\n      study primarily bases on the good efficacy of gemcitabine plus TS-1 and the great potential\n      of local control of concurrent chemoradiotherapy in pancreatic cancer."
        }, 
        "brief_title": "Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer", 
        "condition": "Metastatic Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically or cytologically proven, newly diagnosed pancreatic adenocarcinoma or\n             adenosquamous carcinoma\n\n          -  no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, or\n             immunotherapy used for pancreatic cancer\n\n          -  presence of at least one measurable lesion, which must meet the criteria of being \u2265\n             20 mm in at least one dimension by conventional CT/MRI or \u2265 10 mm by spiral CT scan\n\n          -  age between 20 and 79 years at registration\n\n          -  ECOG PS of 0 or 1\n\n          -  adequate major organ functions\n\n          -  ability to take the oral study medication (TS-1)\n\n          -  no clinically significant abnormal ECG findings within 28 days (4 weeks) prior to\n             registration\n\n          -  voluntarily signed the written informed consent form\n\n        Exclusion Criteria:\n\n          -  pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to\n             registration\n\n          -  presence of diarrhea \u2265 CTCAE v.4.03 grade 2\n\n          -  concomitant active infection or significant co-morbid medical conditions\n\n          -  moderate or severe ascites or pleural effusion that requires drainage\n\n          -  central nervous system metastasis\n\n          -  prior or concurrent malignancies within the last 3 years\n\n          -  concomitant treatment with flucytosine, phenytoin or warfarin\n\n          -  pregnant women or nursing mothers, or positive pregnancy test\n\n          -  severe mental disorder\n\n          -  judged ineligible by physician for participation in the study due to safety concern"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946646", 
            "org_study_id": "201211048MPC"
        }, 
        "intervention": {
            "arm_group_label": "S-1-CCRT", 
            "intervention_name": "S-1-CCRT", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 22, 2013", 
        "location": {
            "contact": {
                "email": "b4401064@yahoo.com.tw", 
                "last_name": "Shih-Hung Yang, MD", 
                "phone": "886-2-23123456", 
                "phone_ext": "71664"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "100"
                }, 
                "name": "National Taiwan University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Shih-Hung Yang, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Kun-Huei Yeh, MD PHD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chiun Hsu, MD PHD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chih-Hung Hsu, MD PHD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sung-Hsin Kuo, MD PHD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yu-Lin Lin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jen-Chieh Lee, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)", 
        "overall_contact": {
            "email": "b4401064@yahoo.com.tw", 
            "last_name": "Shih-Hung Yang, MD", 
            "phone": "886-2-23123456", 
            "phone_ext": "71664"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Dose-limiting toxicities (DLT) are defined as the following manifestations of toxicity observed until completion of CCRT:\ngrade 3 leucopenia and/or neutropenia with a fever \u2265 38\u00b0C lasting 3 days or more\ngrade 3 leucopenia and/or neutropenia with infection\ngrade 4 leucopenia and/or neutropenia lasting 3 days or more\ngrade 4 leucopenia and/or neutropenia requiring G-CSF\nplatelet < 25,000/mm3\n, grade 3 thrombocytopenia requiring transfusion\nhemoglobin < 8.0 g/dL\ng. serum AST/ALT \u2265 10 times ULN h. total bilirubin \u2265 3 times ULN i. creatinine >3.0 - 6.0 times ULN (grade 3) i. grade 3 or 4 nonhematological toxicities including nausea, vomiting, anorexia, fatigue, constipation, hyperglycemia, and abnormality of sodium, potassium, and calcium If three or more patients experience DLT at a given dose level, then the previous dose level will be considered as the MTD.", 
                "measure": "maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "maximum-tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946646"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Taiwan University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "TTY Biopharm", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Taiwan University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}